Renal Cell Cancer: Keynote Lecture From GU Symposium 2015
Toni K. Choueiri, MD, delivered a keynote lecture on recent advances in the treatment of renal cell carcinoma at the 2015 GU Symposium.
Toni K. Choueiri, MD, delivered a keynote lecture on recent advances in the treatment of renal cell carcinoma at the 2015 GU Symposium.
Body mass index (BMI) predicts survival and overall response rates in patients with metastatic clear cell renal cell carcinoma.
Protein expression markers predict disease-specific survival (DSS) in clear cell renal cell carcinoma (ccRCC).
Adjuvant sorafenib and sunitinib do not improve survival for patients with locally advanced renal cell carcinoma (RCC).
Optimal chemotherapy remains unclear for metastatic teratoma with malignant transformation (TMT).
Baseline and changed neutrophil to lymphocyte ratio predict targeted treatment responses in metastatic renal cell carcinoma (mRCC).
Circulating microRNA miR-371a-3p levels appear to be a promising biomarker of tumor bulk in testicular germ cell tumors (GCTs).
Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Dose-escalated radiotherapy does not improve overall survival compared with lower-dose radiotherapy regimens for localized prostate cancer.